OpalGenix, Inc.
OpalGenix is dedicated to enhancing pain management by minimizing opioid risks and maximizing surgical pain relief through personalized, evidence-based technology. Their flagship product, GPS-Opioid™, utilizes pharmacogenetic testing and intelligent analytics to guide precise opioid selection and dosing, aiming to improve patient safety and clinical outcomes.
Industries
Nr. of Employees
small (1-50)
OpalGenix, Inc.
Products
Pre-operative opioid risk prediction test and decision support platform
A combined laboratory test and decision-support platform that integrates genotyping and clinical data to produce individualized risk predictions and prescribing guidance for perioperative opioid management.
Pre-operative opioid risk prediction test and decision support platform
A combined laboratory test and decision-support platform that integrates genotyping and clinical data to produce individualized risk predictions and prescribing guidance for perioperative opioid management.
Services
Pre-operative pharmacogenetic risk testing and clinical decision support
Laboratory service that performs multi-gene pharmacogenetic testing on pre-operative samples and delivers evidence-based decision support to clinicians to guide opioid selection, dosing, monitoring, and follow-up.
Pre-operative pharmacogenetic risk testing and clinical decision support
Laboratory service that performs multi-gene pharmacogenetic testing on pre-operative samples and delivers evidence-based decision support to clinicians to guide opioid selection, dosing, monitoring, and follow-up.
Expertise Areas
- Pharmacogenomics
- Perioperative pain management
- Clinical decision support for medication prescribing
- Clinical translational research
Key Technologies
- Pharmacogenetic testing
- Genotyping assays
- Polygenic risk modeling
- Clinical decision support systems (CDS)